Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04502394
Title Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Kartos Therapeutics, Inc.
Indications

relapsed/refractory diffuse large B-cell lymphoma

chronic lymphocytic leukemia

Therapies

Acalabrutinib + KRT-232

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | BEL

Additional content available in CKB BOOST